Phase 2 Trial
AbbVie Buys Bretisilocin from Gilgamesh in $1.2B Deal to Expand Depression Drug Pipeline–Another Win in the Psychedelic Space?
2025-08-27
Biohaven’s Potential First-in-Class Autoimmune Therapy BHV-1300 Cuts Total IgG by Over 80%
2025-03-04
AusBiotech on Funding, Regulatory Navigation, International Expansion, and Clinical Trial Development in Australia’s Biotech Industry
2024-08-22
Neurocrine, Takeda Look to Build on Positives Post Luvadaxistat’s Schizophrenia Trial Failure
2021-03-03
Gilead and Novo Nordisk Present Proof-of-Concept Data for the First Possible NASH Treatment
2020-11-17
LATEST
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan





